A Study To Assess the Effects Of PF-04457845 On BOLD fMRI In Subjects With Post Traumatic Stress Disorder

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Post-Traumatic Stress Disorder

In brief

The purpose of the study is to evaluate proof of mechanism of PF-04457845, using a well-established neuroimaging paradigm including behavioral tasks selected to activate neuro-circuitry relevant to Post Traumatic Stress Disorder. It is hypothesized that PF-04457845 will modulate the Blood-oxygen-level dependent Functional Magnetic Resonance Imaging signal from the relevant neuro-circuits in patients with Post Traumatic Stress Disorder.

Key facts

Study ID

NCT02216097

Run by

Pfizer

People needed

14

Starts

2014-10-01

Expected to finish

2015-03-01

Last updated by the study team

2016-06-29

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Men and women 18-60 years of age with a primary psychiatric diagnosis of Post Traumatic Stress Disorder

You may not qualify if…

• Other psychiatric illness requiring current treatment with medication.

Where it is running

• Clinical and Translational Science Institute (CTSI) — New York, New York, United States
• NYU CTSI Research Pharmacy (Drug Shipment Address) — New York, New York, United States
• NYU School of Medicine — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.